Clinical practice guidelines for PSA testing and early management of test-detected prostate cancer
Guidelines developed in partnership with
This resource has been developed, reviewed or revised more than five years ago. It may no longer reflect current evidence or best practice.
Published: 2015
National Health and Medical Research Council 
These guidelines (recommendations) in the web-version of this guideline were approved by the Chief Executive Officer of the National Health and Medical Research Council (NHMRC) on 2 November 2015 under section 14A of the National Health and Medical Research Council Act 1992 In approving the guidelines (recommendations), NHMRC considers that they meet the NHMRC standard for clinical practice guidelines. This approval is valid for a period of five years. NHMRC is satisfied that the guidelines (recommendations) are systematically derived, based on the identification and synthesis of the best available scientific evidence, and developed for health professionals practising in an Australian health care setting.
This publication reflects the views of the authors and not necessarily the views of the Australian Government.Endorsed by
Download
Note: Please note that the relevant excerpt pages of the technical report are accessible in the appendix of each content page.
Introduction
1 Risk
2 Testing
2.1. Decision support for men considering PSA testing
2.3. Role of digital rectal examination
2.4. PSA testing and life expectancy
2.5. Testing with variants of PSA to improve sensitivity after an initial total PSA ≤ 3.0 ng/mL
3 Prostate biopsy and multiparametric MRI
3.2. Follow-up to a negative prostate biopsy
4 Active surveillance
5 Watchful waiting
6 Sociocultural aspects of PSA Testing in Australia
Appendices
Appendix 1 Guideline development process
Appendix 2 Committee members and contributors
Appendix 3 List of clinical questions
Appendix 4 TNM classification of prostate tumours